ArticleFrontiers in microbiology2020
Carbapenemase-Producing
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- Genomics of Hospital-Associated Brazilian Multidrug-Resistant Klebsiella pneumoniae: Abundance of Resistance and Virulence Genes and Mosaicism of the blaCurrent microbiology · 2026Article
- COVID-19 pandemic-driven evolution of Klebsiella pneumoniae: rising resistance, genetic diversity, and virulence in a Brazilian tertiary hospital.Einstein (Sao Paulo, Brazil) · 2026Article
- Nationwide Burden of Metallo-β-Lactamase Genes in Brazilian ClinicalAntibiotics (Basel, Switzerland) · 2025Review
- Impact of the COVID-19 Pandemic on Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Effect of Meropenem on Conjugative Plasmid Transfer inInternational journal of molecular sciences · 2024Article
- ESKAPE in China: epidemiology and characteristics of antibiotic resistance.Emerging microbes & infections · 2024Review
- Comparative Meropenem Pharmacodynamics and Emergence of Resistance against Carbapenem-Susceptible Non-Carbapenemase-Producing and Carbapenemase-Producing Enterobacterales: A Pharmacodynamic Study in a Hollow-Fiber Infection Model.Antibiotics (Basel, Switzerland) · 2023Article
- Emergence of KPC-113 and KPC-114 variants in ceftazidime-avibactam-resistantMicrobiology spectrum · 2023Article
- A Review of Carbapenem Resistance inMicroorganisms · 2023Review
- Global emergence of carbapenem-resistantComputational and structural biotechnology journal · 2023Article
- Genomics ofMicroorganisms · 2022Article
- Next-Generation Sequencing of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Current status of NDM-producing Enterobacterales in Brazil: a narrative review.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Review
- Extended-spectrum β-lactamase-producing and carbapenem-resistant Enterobacterales bloodstream infection after solid organ transplantation: Recent trends in epidemiology and therapeutic approaches.Transplant infectious disease : an official journal of the Transplantation Society · 2022Review
- Plethora of Resistance Genes in Carbapenem-Resistant Gram-Negative Bacteria in Greece: No End to a Continuous Genetic Evolution.Microorganisms · 2022Article
- Evaluation of Fourier Transform Infrared Spectroscopy as a First-Line Typing Tool for the Identification of Extended-Spectrum β-Lactamase-ProducingFrontiers in microbiology · 2022Article
- The Gastrointestinal Load of Carbapenem-Resistant Enterobacteriacea Is Associated With the Transition From Colonization to Infection byFrontiers in cellular and infection microbiology · 2022Article
- The Spread of NDM-1 and NDM-7-ProducingAntibiotics (Basel, Switzerland) · 2021Article
- Genetic Basis of Antimicrobial Resistant Gram-Negative Bacteria Isolated From Bloodstream in Brazil.Frontiers in medicine · 2021Article
- Molecular Epidemiology of Carbapenemases inAntibiotics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCarbapenemase-producing
methodsOne
resultsThe mortality rate of CP-Kp colonized or infected transplanted inpatients was 21.3% (17/80). Four CP-Kp epidemic clones were described: ST11/KPC-2, ST16/KPC-2, and ST15/NDM-1, all responsible for interhospital outbreaks; and ST437/KPC-2 affecting a single hospital. The average number of acquired resistance and virulence genes was 9 (range = 2-14) and 27 (range = 6-36), respectively. Two plasmids carrying the
conclusionWe detected intrahospital and interhospital spread of mobile structures and international
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.